All Articles

Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.

A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.

The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.

Looking for inspiring and educational programming for oncology navigators? Look no further than AONN+!

Providing patient education that meets patients’ cultural, literacy, and learning styles can increase patient self-care and satisfaction and improve health outcomes.

Thirty-one biosimilar products have been approved by the FDA, 20 of which have been launched in the United States.

An understanding of the history of racism is required to reduce disparities in cancer care, from investigational research to treatment, agreed a panel that examined barriers to equitable care and potential solutions to remove these barriers.

Oncology therapeutics continue to be a dominant component of the treatment paradigm, and thus, specialized oncology pharmacy programs play an ever-increasing role in the complex delivery of care.

The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic. Here’s what the experts anticipate in the future of telehealth services.

Pandemic-inspired innovations will play an important role in the future of cancer care delivery.